子宮内膜症治療薬の世界市場予測・分析2019-2023

◆英語タイトル:Endometriosis Drugs Market by Product, RoA, and Geography - Global Forecast & Analysis 2019-2023
◆商品コード:IRTNTR32107
◆発行会社(リサーチ会社):Technavio
◆発行日:2019年9月30日
◆ページ数:159
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥260,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥312,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥416,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

Technavio社の本調査レポートでは、子宮内膜症治療薬の世界市場について調べ、子宮内膜症治療薬の市場状況、市場規模、市場予測、市場環境、顧客状況、市場動向、関連企業情報などをまとめました。また、子宮内膜症治療薬の市場規模をセグメンテーション別(製品別(ホルモン療法、鎮痛薬)、)と地域別(グローバル)に分けて算出しました。Technavio社は子宮内膜症治療薬の世界市場規模が2019-2023期間中に年平均3%成長すると予測しています。
・サマリー
・レポートの範囲
・子宮内膜症治療薬の市場状況
・子宮内膜症治療薬の市場規模
・子宮内膜症治療薬の市場予測
・子宮内膜症治療薬の世界環境:ファイブフォース分析
・市場セグメンテーション:製品別(ホルモン療法、鎮痛薬)
・子宮内膜症治療薬の顧客状況
・主要地域別市場規模:グローバル
・意思決定フレームワーク
・市場動向・成長要因・課題
・関連企業状況・企業分析
 ...
【レポートの概要】

Global Endometriosis Drugs Market: About this market
Technavio’s endometriosis drugs market analysis considers sales from both hormone therapy and analgesics products. Our report also finds the sales of endometriosis drugs in Asia, Europe, North America, and ROW. In 2018, the hormone therapy segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the introduction of novel drug delivery systems will play a vital role in the hormone therapy segment to maintain its market position. Also, our global endometriosis drugs market report looks at factors such as recent approvals of advanced diagnostics, rising focus on women’s health, and popularity of novel drug delivery systems. However, the suppressive nature of available therapies, side effects of OCPs, and clinical trial failures may hamper the growth of the endometriosis drugs industry over the forecast period.

Global Endometriosis Drugs Market: Overview
Rising focus on women’s health
The increasing focus emphasis on women’s health is expected to boost the growth of the endometriosis drugs market size during the forecast period. Lack of awareness about several gynecological cancer indications such as endometriosis and endometrial cancer was a challenge for the growth of the market. However, various governmental authorities and organizations are working to raise awareness to overcome such challengesproblems. For instance, the Office on Women’s Health (OWH), which is a part of the US Department of Health and Human Services (HHS), coordinates women’s health efforts and addresses critical women’s health issues by informing and advancing policies and educating healthcare professionals and consumers. This focus on women’s health will lead to the expansion of the global endometriosis drugs market at a CAGR of over 3% during the forecast period.

Availability of patient assistance programs
The endometriosis drug market is dominated by high-cost hormone-based therapeutics, which is a significant concern for patients. Thus, companies such as AbbVie and Bayer are providing patient-assistance programs to reduce the cost burden on patients. The availability of patient assistance programs for high-cost branded drugs will increase patient adherence to such drugsmedications, which is expected to have a positive impact on the overall market growth.
For the detailed list of factors that will drive the global endometriosis drugs market during the forecast period 2019-2023, click here.

Competitive Landscape
With the presence of several major players, the global endometriosis drug market is moderately fragmented. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading endometriosis drugs manufacturers, that include AbbVie Inc., Allergan Plc, AstraZeneca Plc, Bayer AG, Johnson & Johnson Services Inc., Mayne Pharma Group Ltd., Merck & Co., Inc., Pfizer Inc., Takeda Pharmaceutical Co. Ltd., and Teva Pharmaceutical Industries Ltd.
Also, the endometriosis drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming future growth opportunities.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
• PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• Hormone therapy – Market size and forecast 2018-2023
• Analgesics – Market size and forecast 2018-2023
• Market opportunity by product
PART 07: MARKET SEGMENTATION BY ROA
PART 08: CUSTOMER LANDSCAPE
PART 09: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America – Market size and forecast 2018-2023
• Europe – Market size and forecast 2018-2023
• Asia – Market size and forecast 2018-2023
• ROW – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 10: DECISION FRAMEWORK
PART 11: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 12: MARKET TRENDS
• Strategic alliances
• Robust pipeline
• Availability of patient-assistance programs
PART 13: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 14: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• AbbVie Inc.
• Allergan Plc
• AstraZeneca Plc
• Bayer AG
• Johnson & Johnson Services Inc.
• Mayne Pharma Group Ltd.
• Merck & Co., Inc.
• Pfizer Inc.
• Takeda Pharmaceutical Co. Ltd.
• Teva Pharmaceutical Industries Ltd.
PART 15: APPENDIX
• Research methodology
• List of abbreviations
• Definition of market positioning of vendors
PART 16: EXPLORE TECHNAVIO


Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2018
Exhibit 18: Product – Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Hormone therapy – Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Hormone therapy – Year-over-year growth 2019-2023 (%)
Exhibit 22: Analgesics – Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Analgesics – Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by product
Exhibit 25: Market segmentation by RoA: Overview
Exhibit 26: Customer landscape
Exhibit 27: Market share by geography 2018-2023 (%)
Exhibit 28: Geographic comparison
Exhibit 29: North America – Market size and forecast 2018-2023 ($ millions)
Exhibit 30: North America – Year-over-year growth 2019-2023 (%)
Exhibit 31: Top 3 countries in North America
Exhibit 32: Europe – Market size and forecast 2018-2023 ($ millions)
Exhibit 33: Europe – Year-over-year growth 2019-2023 (%)
Exhibit 34: Top 3 countries in Europe
Exhibit 35: Asia – Market size and forecast 2018-2023 ($ millions)
Exhibit 36: Asia – Year-over-year growth 2019-2023 (%)
Exhibit 37: Top 3 countries in Asia
Exhibit 38: ROW – Market size and forecast 2018-2023 ($ millions)
Exhibit 39: ROW – Year-over-year growth 2019-2023 (%)
Exhibit 40: Top 3 countries in ROW
Exhibit 41: Key leading countries
Exhibit 42: Market opportunity
Exhibit 43: Side effects of OCPs used for treatment of endometriosis
Exhibit 44: Impact of drivers and challenges
Exhibit 45: Drug development pipeline late-stage molecules for treatment of endometriosis
Exhibit 46: Vendor landscape
Exhibit 47: Landscape disruption
Exhibit 48: Vendors covered
Exhibit 49: Vendor classification
Exhibit 50: Market positioning of vendors
Exhibit 51: AbbVie Inc. – Vendor overview
Exhibit 52: AbbVie Inc. – Business segments
Exhibit 53: AbbVie Inc. – Organizational developments
Exhibit 54: AbbVie Inc. – Geographic focus
Exhibit 55: AbbVie Inc. – Key offerings
Exhibit 56: AbbVie Inc. – Key customers
Exhibit 57: Allergan Plc – Vendor overview
Exhibit 58: Allergan Plc – Business segments
Exhibit 59: Allergan Plc – Organizational developments
Exhibit 60: Allergan Plc – Segment focus
Exhibit 61: Allergan Plc – Key offerings
Exhibit 62: Allergan Plc – Key customers
Exhibit 63: AstraZeneca Plc – Vendor overview
Exhibit 64: AstraZeneca Plc – Business segments
Exhibit 65: AstraZeneca Plc – Organizational developments
Exhibit 66: AstraZeneca Plc – Geographic focus
Exhibit 67: AstraZeneca Plc – Key offerings
Exhibit 68: AstraZeneca Plc – Key customers
Exhibit 69: Bayer AG – Vendor overview
Exhibit 70: Bayer AG – Business segments
Exhibit 71: Bayer AG – Organizational developments
Exhibit 72: Bayer AG – Geographic focus
Exhibit 73: Bayer AG – Segment focus
Exhibit 74: Bayer AG – Key offerings
Exhibit 75: Bayer AG – Key customers
Exhibit 76: Johnson & Johnson Services, Inc. – Vendor overview
Exhibit 77: Johnson & Johnson Services, Inc. – Business segments
Exhibit 78: Johnson & Johnson Services, Inc. – Organizational developments
Exhibit 79: Johnson & Johnson Services, Inc. – Geographic focus
Exhibit 80: Johnson & Johnson Services, Inc. – Segment focus
Exhibit 81: Johnson & Johnson Services, Inc. – Key offerings
Exhibit 82: Johnson & Johnson Services, Inc. – Key customers
Exhibit 83: Mayne Pharma Group Ltd. – Vendor overview
Exhibit 84: Mayne Pharma Group Ltd. – Business segments
Exhibit 85: Mayne Pharma Group Ltd. – Organizational developments
Exhibit 86: Mayne Pharma Group Ltd. – Geographic focus
Exhibit 87: Mayne Pharma Group Ltd. – Segment focus
Exhibit 88: Mayne Pharma Group Ltd. – Key offerings
Exhibit 89: Mayne Pharma Group Ltd. – Key customers
Exhibit 90: Merck & Co. Inc. – Vendor overview
Exhibit 91: Merck & Co. Inc. – Business segments
Exhibit 92: Merck & Co. Inc. – Organizational developments
Exhibit 93: Merck & Co. Inc. – Geographic focus
Exhibit 94: Merck & Co. Inc. – Segment focus
Exhibit 95: Merck & Co. Inc. – Key offerings
Exhibit 96: Merck & Co. Inc. – Key customers
Exhibit 97: Pfizer Inc. – Vendor overview
Exhibit 98: Pfizer Inc. – Business segments
Exhibit 99: Pfizer Inc. – Organizational developments
Exhibit 100: Pfizer Inc. – Geographic focus
Exhibit 101: Pfizer Inc. – Segment focus
Exhibit 102: Pfizer Inc. – Key offerings
Exhibit 103: Pfizer Inc. – Key customers
Exhibit 104: Takeda Pharmaceutical Co. Ltd. – Vendor overview
Exhibit 105: Takeda Pharmaceutical Co. Ltd. – Business segments
Exhibit 106: Takeda Pharmaceutical Co. Ltd. – Organizational developments
Exhibit 107: Takeda Pharmaceutical Co. Ltd. – Geographic focus
Exhibit 108: Takeda Pharmaceutical Co. Ltd. – Key offerings
Exhibit 109: Takeda Pharmaceutical Co. Ltd. – Key customers
Exhibit 110: Teva Pharmaceutical Industries Ltd. – Vendor overview
Exhibit 111: Teva Pharmaceutical Industries Ltd. – Business segments
Exhibit 112: Teva Pharmaceutical Industries Ltd. – Organizational developments
Exhibit 113: Teva Pharmaceutical Industries Ltd. – Segment focus
Exhibit 114: Teva Pharmaceutical Industries Ltd. – Key offerings
Exhibit 115: Teva Pharmaceutical Industries Ltd. – Key customers
Exhibit 116: Validation techniques employed for market sizing
Exhibit 117: Definition of market positioning of vendors



【掲載企業】

AbbVie Inc.
Allergan Plc
AstraZeneca Plc
Bayer AG
Johnson & Johnson Services Inc.
Mayne Pharma Group Ltd.
Merck & Co., Inc.
Pfizer Inc.
Takeda Pharmaceutical Co. Ltd.
Teva Pharmaceutical Industries Ltd

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[子宮内膜症治療薬の世界市場予測・分析2019-2023]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆